KRAS and cancer: Immunoediting of neoantigens, reduced HLA expression and inactivation of the IFN-γ pathway are perhaps the most ubiquitous examples of immune evasion in KRAS-mutant PD-L1 + cancers, while acquired resistance to immunotherapies tends to be more nuanced.